CervoMed (CRVO) vs Lite Strategy (LITS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lite Strategy (LITS) has outperformed CervoMed (CRVO) over the past year, losing 52.8% versus a loss of 83.6%. Over five years, CRVO leads with a -95.0% price change compared with -98.5% for LITS. Lite Strategy is the larger company by market cap ($24.0 million vs $22.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | LITS |
|---|---|---|
| Share price | $1.46 | $0.8026 |
| Market cap | $22.09M | $23.99M |
| 1-day change | +9.77% | -4.03% |
| YTD return | -81.52% | -39.20% |
| 1-year return | -83.56% | -52.79% |
| 5-year return | -95.01% | -98.46% |
| EPS (TTM) | $-2.65 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.01M | — |
| Revenue growth (YoY) | -58.86% | — |
| Net income (latest FY) | $-26.97M | $-71.15M |
| Operating margin | -706.22% | — |
| Net margin | -673.06% | — |
| 52-week high | $10.00 | $1.99 |
| 52-week low | $1.27 | $0.69 |
| Distance from 52-week high | -85.40% | -59.67% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +954.79% | — |
| Average volume | 489.10K | 524.33K |
| Shares outstanding | 15.13M | 29.88M |
| Employees | 15 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LITS has outperformed CRVO by 30.8 percentage points over the past year.
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CRVO vs LITS FAQ
Which is bigger, CervoMed or Lite Strategy?
Lite Strategy (LITS) is larger, with a market capitalization of $23.99M compared with $22.09M for CervoMed (CRVO).
Which stock has performed better over the past year, CRVO or LITS?
LITS returned -52.79% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and Lite Strategy in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.